ASH News Daily 2012 - Saturday, December 8, 2012 - (Page A-1)

ASH NEWS DAILY 54th Annual Meeting of the American Society of Hematology ® Read this issue online at SCHEDULE 11:15 – 12:15 p.m. Grassroots Network Lunch International Ballroom D, North Tower Omni Hotel at CNN Center 12:30 – 1:30 p.m. Ham-Wasserman Lecture Hall B5, Level 1, Building B, GWCC 2:00 – 3:30 p.m. Special Symposium: Quality Improvement A103, Level 1, Building A GWCC 4:00 – 5:30 p.m. Special Symposium on Epigenetics in Hematopoiesis A103, Level 1, Building A 5:30 – 7:30 p.m. Welcome Reception Poster Hall Hall B1-B2, Level 1, Building B GWCC 6:00 – 7:30 p.m. Practice Forum International Ballroom D, North Tower Omni Hotel at CNN Center 6:30 – 9:00 p.m. Promoting Minorities in Hematology Presentations and Reception Grand Ballroom A-D, M4/Grand Ballroom Level, North Tower Omni Hotel at CNN Center 7:30 – 8:30 p.m. Practice Forum Reception Grand Ballroom A-B, M2/Grand Ballroom Level, North Tower Omni Hotel at CNN Center ASH shuttle buses remind attendees to “Fight for Hematology” as they drive in front of the Georgia World Congress Center on Friday morning. ASH – The OTHER Helpful Hardware Place BY ANDREW D. LEAVITT, MD Y underlying ou know the presenting signs and symptoms for myriad hematologic disorders, their pathophysiology, and the latest medications and practice guidelines. You are revered as the go-to hematologist in your area when all others are stumped. But do you have the right environmental structure, the right toolkit, to translate that wealth of knowledge and expertise into objective, high-quality patient care in your practice? If you are like many of us, the answer is no. With the current and upcoming changes in health-care delivery and reimbursement, this toolkit will be essential for you to continue doing what you enjoy, and to do it well. To that end, today, at 2:00 p.m. in Room A103, on Level 1 of Building A in the Georgia World Congress Center, you can update your wealth of knowledge at the “Special Symposium on Quality Improvement – A Toolkit for Hematology Practice.” Symposium Co-chairs John Strouse, MD, PhD, of Johns Hopkins University, Baltimore, MD, and Wendy Lim, MD, of McMaster University, Hamilton, ON, are members of the ASH Subcommittee on Quality of Care and have assembled an outstanding team to provide you with practical quality improvement tools. Charles J. Homer, MD, from the National Initiative for Children’s Healthcare Quality, Boston, MA, will kick off the symposium with an insightful and practical overview of the principles and implementation tools necessary to achieve real quality health-care outcome improvement. Dr. Homer’s presentation, »» QUALITY Page A-5 The Ham-Wasserman Lecture Reveals the UK Point of View on AML BY JENNA D. GOLDBERG, MD IN THIS SECTION Exemplary Service Award A-3 Pediatric Leukemias A-4 Myeloma A-8 TTP/HUS A-14 Transplantation A-18 for many years. Patients who are deemed fit enough generally receive induction therapy affectionately termed “7+3” with cytarabine combined with an anthracycline. Consolidation therapy is usually additional cytarabine or an allogeneic stem cell transplant for otherwise healthy patients with high-risk disease. This outdated paradigm will be challenged by Dr. Alan K. Burnett in today’s Ham-Wasserman Lecture. T In this afternoon’s lecture, Dr. Burnett will discuss the personalization of leukemia therapy. He will review recent data that may suggest that there are better induction op- he standard therapy for acute myeloid leukemia (AML) has remained unchanged tions than the traditional “7+3” approach, particularly for younger patients. A few of the options that he will review include daunorubicin intensification, inclusion of novel nucleoside analogues (fludarabine/ clofarabine/cladribine), and the incorporation of antibody-directed chemotherapy using gemtuzumab ozogamicin, which the Medical Research Council (MRC) has adopted as a standard of care, in spite of the regulatory limitations. The strategy for determining who receives an allogeneic transplant in first remission will be addressed, including incorporating molecular studies and minimal residual disease testing. Dr. Burnett will also discuss the implications of molecular testing on treatment, including targeting FLT3/mTOR and BCL2 with all-trans-retinoic acid as examples, although none has yet Ham-Wasserman Lecture 12:30 p.m. Hall B5, Building B, Level 1 Georgia World Congress Center shown clear benefit in a randomized trial. Finally, he will talk about the lack of progress in improving outcomes in older patients and the novel “pick-a-winner” design he helped develop that has the potential to more rapidly evaluate new treatments or combinations for this patient group, which may apply to »» HAM-WASSERMAN Page A-5

Table of Contents for the Digital Edition of ASH News Daily 2012 - Saturday, December 8, 2012

ASH News Daily 2012 - Saturday, December 8, 2012